{"disease":{"id":"pancreatic-neuroendocrine-carcinoma","name":"pancreatic neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00830557","title":"Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04483349","title":"Assessment of What Patients and Healthcare Providers Value","phase":"","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT02955069","title":"Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07006727","title":"Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03616431","title":"Pancreatic Cancer Dietary Assessment Study","phase":"","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT02595424","title":"Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":67,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT03884179","title":"Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy","phase":"","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT05251233","title":"Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":56,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03600233","title":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"TaiRx, Inc.","has_results":false},{"nct_id":"NCT05247905","title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04514497","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02101918","title":"Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02893930","title":"Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03736720","title":"Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03435770","title":"Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Singapore General Hospital","has_results":false},{"nct_id":"NCT03042780","title":"FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04644315","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}